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Abstract
Aberrant activation of the Wnt/b-catenin pathway is critical for the initiation and progression of most colon cancers. This
activation provokes the accumulation of nuclear b-catenin and the induction of its target genes. Apc
min/+ mice are the most
commonly used model for colon cancer. They harbor a mutated Apc allele and develop intestinal adenomas and carcinomas
during the first months of life. This phenotype is caused by the mutation of the second Apc allele and the consequent
accumulation of nuclear b-catenin in the affected cells. Here we describe that vitamin D receptor (VDR) is a crucial
modulator of nuclear b-catenin levels in colon cancer in vivo. By appropriate breeding of Apc
min/+ mice and Vdr
+/2 mice we
have generated animals expressing a mutated Apc allele and two, one, or none Vdr wild type alleles. Lack of Vdr increased
the number of colonic Aberrant Crypt Foci (ACF) but not that of adenomas or carcinomas in either small intestine or colon.
Importantly, colon ACF and tumors of Apc
min/+Vdr
-/- mice had increased nuclear b-catenin and the tumors reached a larger
size than those of Apc
min/+Vdr
+/+. Both ACF and carcinomas in Apc
min/+Vdr
-/- mice showed higher expression of b-catenin/
TCF target genes. In line with this, VDR knock-down in cultured human colon cancer cells enhanced b-catenin nuclear
content and target gene expression. Consistently, VDR depletion abrogated the capacity of 1,25(OH)2D3 to promote the
relocation of b-catenin from the nucleus to the plasma membrane and to inhibit b-catenin/TCF target genes. In conclusion,
VDR controls the level of nuclear b-catenin in colon cancer cells and can therefore attenuate the impact of oncogenic
mutations that activate the Wnt/b-catenin pathway.
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Introduction
Colon cancer is the second most common cause of death from
cancer in developed countries [1]. Probably, we know more about
the genetic alterations causing colon cancer than for any other
solid neoplasia. Mutations in APC/adenomatous polyposis coli,
CTNNB1/b-catenin or AXIN genes which activate Wnt/b-catenin
pathway are responsible for the initiation of most colon cancers
[2]. The first step of colon tumorigenesis involves the formation of
Aberrant Crypt Foci (ACF), which later progress to adenoma [3].
Posterior malignization of adenoma to carcinoma requires the
acquisition of new alterations in genes which are related to Wnt/b-
catenin signaling or belong to other pathways that act synergis-
tically in the process [2].
Apc
min/+ mice harboring a germ line inactivating mutation in
one Apc allele develop multiple intestinal adenomas and carcino-
mas after three months of age [4]. This phenotype occurs as a
consequence of spontaneous mutation of the remaining Apc allele
(loss of heterozygosity) and the activation of the Wnt/b-catenin
signaling pathway. This mouse model has become the gold
standard of intestinal cancer initiation.
Wnt/b-catenin pathway regulates the ability of b-catenin
protein to drive the regulation of specific target genes [5,6]. In
brief, in the absence of a Wnt signal or activating mutations, b-
catenin is only present bound to E-cadherin in the intercellular
adherens junctions, as the free protein is rapidly phosphorylated by
casein kinase-Ib (CK-Ia) (Ser45) and glycogen synthase kinase-3
(GSK-3b) (Ser33, Ser37 and Thr41) in a complex formed also by
the tumor suppressor proteins APC and Axin. Phosphorylation
labels b-catenin for ubiquitination and degradation by the
proteasome [7]. In such basal conditions DNA-bound T-cell
factor/lymphoid enhancer factor (TCF/LEF) proteins interact
with transcriptional corepressors to block target gene expression in
the nucleus. Binding of Wnt ligands to their cell surface receptor
complexes (Frizzled-LRP) results in the recruitment of cytoplasmic
Axin to the plasma membrane, activation of Dishevelled protein
and other not well characterized effects that lead to the inhibition
of b-catenin phosphorylation. This allows b-catenin to accumulate
and enter into the nucleus, where it interacts with TCF/LEF
family members and causes the activation of their otherwise
repressed target genes [5,7]. The Wnt/b-catenin pathway is the
main driving force behind the proliferation of epithelial cells in the
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compartments [8,9]. However, the mutations found in colon
cancer result in the aberrant activation of the pathway and induce
the constitutive expression of its target genes (mainly involved in
cell proliferation and dedifferentiation), leading to the formation of
benign yet long-lived adenomas. Accumulation of additional
genetic and epigenetic alterations fuels tumor progression.
Many epidemiological and experimental studies indicate that
vitamin D3 (cholecalciferol), its most active metabolite 1a,25-
dihydroxyvitamin D3 (calcitriol, 1,25(OH)2D3) and several analogs
protect against colon cancer [10-12]. We have reported that
1,25(OH)2D3 inhibits proliferation and promotes epithelial
differentiation of human colon cancer cells by inducing the
expression of E-cadherin and by antagonizing the Wnt/b-catenin
pathway. The latter is the result of two main mechanisms: a) the
induction of direct binding of vitamin D receptor (VDR) to b-
catenin, which precludes the formation of transcriptionally active
b-catenin/TCF complexes, and b) the induction of b-catenin
nuclear export and relocalization at plasma membrane adherens
junctions as a consequence of E-cadherin upregulation [13].
Additionally, 1,25(OH)2D3 increases the expression of DICK-
KOPF-1 (DKK1), a secreted protein that inhibits Wnt signaling
from its plasma membrane receptors [14]. We have also described
that human VDR gene is a direct target of SNAIL1 and SNAIL2/
SLUG transcription repressors, and that VDR expression in colon
cancer patients is reduced at advanced stages of the disease
associated to the upregulation of these factors [15,16]. Accord-
ingly, high SNAIL1/2 expression in cultured colon cancer cells
increases b-catenin transcriptional activity by repressing VDR
expression and its antagonistic activity on Wnt/b-catenin signaling
[16,17].
b-Catenin has a wide range of pleiotropic effects that cannot
probably be explained solely by the modulation of TCF/LEF
action. Thus, b-catenin has been recently described to bind several
transcription factors of the nuclear receptor superfamily and
homeobox proteins [13,18,19]. In most cases, b-catenin binding
enhances the transcriptional activity of these factors and affects the
expression of alternative or additional sets of target genes involved
in cell-fate decisions along development, tissue homeostasis, or
cancer [19,20]. Our initial description of the direct interaction of
b-catenin with VDR in human colon cancer cells has been
confirmed in other cell systems [21–24]. b-catenin/VDR interac-
tion involves the activator function-2 (AF-2) transactivation
domain of VDR and the C-terminal domain of b-catenin [21].
In mouse skin, b-catenin/VDR controls target genes, epithelial
stem cell fate and tumor development [20]. In this system,
increased nuclear b-catenin promoted tumor initiation while VDR
ligands protect against cancer by reducing the strength of Wnt/b-
catenin signaling [20]. Consistent with this, the treatment of
Apc
min/+ mice with 1,25(OH)2D3 or analogs reduces tumor load
[25] or polyp number and load [26].
It is important to highlight that the level of b-catenin in the
nucleus define the strength of the Wnt signal and in consequence
the fate or behavior of several types of normal and tumoral cells
[5,27]. In addition to activating mutations of the Wnt/b-catenin
pathway components, other genetic alterations like mutations in K-
RAS [28] or activation of oncogenic pathways like HGF/c-Met
signaling [29] enhance nuclear b-catenin accumulation during
colon cancer progression. In such scenario, agents able to diminish
b-catenin nuclear content and so to attenuate Wnt/b-catenin
signal could be potentially used in cancer therapy as long as tumor
cells show Wnt pathway addiction.
In this study we evaluate the consequences of VDR deficiency on
the initiation and development of intestinal cancer driven by the
activation of Wnt/b-catenin pathway. The effect of VDR absence
has been analyzed both in vivo and in vitro: in tumors generated in
Apc
min/+Vdr
-/- mice and in cultured human colon cancer cells in
which VDR expression was knocked-down by means of shRNA. In
addition, we have studied the effect of VDR reconstitution in
VDR-negative human colon cancer cells. Our results establish a
direct link between VDR function and nuclear b-catenin levels
that is crucial to control the activity of Wnt/b-catenin signaling in
colon cancer in vivo.
Results
Using available Apc
min/+ and Vdr
+/2 mice we generated by
appropriate crossings Apc
min/+Vdr
+/+,A p c
min/+Vdr
+/2 and Apc
min/+
Vdr
-/- animals. Histological analysis at five months of age revealed
that Vdr deficiency did not affect the total number of tumors in
Apc
min/+ mice, either in the small intestine or in the colon (Figure 1a,
1b). In contrast, colon tumors inApc
min/+Vdr
-/- mice were significantly
larger than in Apc
min/+Vdr
+/+ or Apc
min/+Vdr
+/2 mice (Figure 1c).
Although different in size, colon adenomas and carcinomas were
histopathologically equivalent in all mice independently of their Vdr
status (Figure 1d). In addition, the number of colonic ACF was higher
in Apc
min/+Vdr
-/- mice than in Apc
min/+Vdr
+/+ or Apc
min/+Vdr
+/- mice
(Figure 2a).
Next we evaluated the status of Wnt pathway activation in colon
lesions by analyzing b-catenin expression. Although ACF in
Apc
min/+Vdr
+/+, Apc
min/+Vdr
+/- and Apc
min/+Vdr
-/- mice were indis-
tinguishable by hematoxylin/eosin (H/E) staining, we observed a
net increase in nuclear and cytosolic b-catenin levels in the
complete absence of Vdr (Figure 2b). Whereas b-catenin staining
was high and quite homogeneous among cells in ACF (Figure 2b),
it was very heterogeneous in carcinomas of the three types of
animals (Figure S1a). This phenomenon was also observed in
human primary colon carcinomas (Figure S1b), in which the level
of nuclear b-catenin is heterogeneous and probably defines the
tumorigenic potential of different populations of cancer cells
present in the tumor [29]. This heterogeneity may explain why a
statistically significant increase in nuclear b-catenin level was
found in ACF of Apc
min/+Vdr
-/- as compared to Apc
min/+Vdr
+/+ or
Apc
min/+Vdr
+/2 mice (Figure 2c), but only a minor trend was
observed in adenomas and carcinomas (Figure 2d).
To demonstrate a causal link between VDR loss and the increase
in nuclear b-catenin, we studied SW480-ADH human colon
cancer cells in which VDR was knocked-down by means of
shRNA. These cells harbor most of genetic abnormalities that
characterize advanced colon cancers such as mutation of APC and
TP53 tumor suppressor genes, activation of K-RAS oncogene and
c-MYC amplification [13]. In agreement with the in vivo results, a
strong increase in nuclear b-catenin content was found in shVDR
SW480-ADH cells as compared to shControl cells (Figure 3a, 3b).
In addition, VDR knock-down abrogated the capacity of
1,25(OH)2D3 to induce E-cadherin expression and b-catenin
relocation from the nucleus to the plasma membrane (Figure 3a).
Also, VDR knock-down prevented the reorganization of b-tubulin
cytoskeleton and the change in cell morphology induced by
1,25(OH)2D3 that leads to the formation of compact epithelioid
islands (Figure 3b).
We wished to analyze whether the increase in the level of
nuclear b-catenin translated into a stronger Wnt/b-catenin
signaling. To this end, we studied b-catenin/TCF-dependent
transcription in colon cancer cells. shControl and shVDR SW480-
ADH cells were infected with lentiviruses encoding the reporter
eGFP protein under the control of seven copies of a consensus
TCF/LEF binding site (Figure 4a) [30]. The presence in the
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min/+ mice. Total number of tumors (adenomas and carcinomas)
in the small intestine (a) or in the colon (b) of Apc
min/+Vdr
+/+, Apc
min/+Vdr
+/2 and Apc
min/+Vdr
-/- mice. Each dot corresponds to one mouse analyzed and
the horizontal line indicates the mean. (c) Size of colon tumors (adenomas and carcinomas) from Apc
min/+Vdr
+/+, Apc
min/+Vdr
+/- and Apc
min/+Vdr
-/- mice.
Each dot corresponds to one tumor analyzed and the horizontal line indicates the mean. The p-value for one-way ANOVA analysis is shown. Asterisks
indicate significant differences between groups upon Bonferroni multiple comparison post-test. (d) Representative hematoxylin/eosin staining
images of colon carcinomas from Apc
min/+Vdr
+/+ and Apc
min/+Vdr
-/- mice. Scale bar, 300 mm.
doi:10.1371/journal.pone.0023524.g001
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controlled by a constitutive promoter permitted to identify infected
cells under a fluorescent microscope and by flow cytometry.
Similarly to b-catenin staining in colon tumors, we found certain
heterogeneity in b-catenin/TCF activity among the cell culture:
variable eGFP expression in equally infected cells (Figure 4b). The
analysis of the whole cell population by flow cytometry showed
that the percentage of high-eGFP cells was superior in shVDR
than in shControl cell cultures (Figure 4c). In addition, shVDR
cells had a significantly higher eGFP signal average than
shControl cells (Figure 4d). We also found that the decrease in
eGFP accumulation caused by 1,25(OH)2D3 in shControl cells
(reduction of the percentage of high-eGFP cells and of eGFP signal
average) was attenuated in shVDR cells (Figure 4c, 4d).
Figure 3. VDR knock-down in SW480-ADH human colon cancer cells increases b-catenin nuclear level. Representative
immunofluorescence images showing b-catenin and E-cadherin (a) or b-catenin and b-tubulin (b) expression and localization in SW480-ADH cells
infected with lentiviruses expressing shVDR or shControl and treated with 1,25(OH)2D3 or vehicle for 72 h. Scale bar, 20 mm.
doi:10.1371/journal.pone.0023524.g003
Figure 2. b-Catenin nuclear level is elevated in colonic lesions of Apc
min/+Vdr
-/- mice. (a) Total number of colonic ACF in Apc
min/+Vdr
+/+,
Apc
min/+Vdr
+/2 and Apc
min/+Vdr
-/- mice. Each dot corresponds to one mouse analyzed and the horizontal line indicates the mean. (b) Upper panels,
representative hematoxylin/eosin staining images of colonic ACF in Apc
min/+Vdr
+/+ and Apc
min/+Vdr
-/- mice. Arrowheads indicate the ACF. Scale bar,
50 mm. Middle panels, representative immunofluorescence images showing b-catenin expression and localization in colonic ACF from Apc
min/+Vdr
+/+
and Apc
min/+Vdr
-/- mice. Arrowheads indicate the ACF. Scale bar, 100 mm. Lower panels are a magnification of middle panels. Scale bar, 50 mm. (c)
Quantification of b-catenin nuclear level in colonic ACF from Apc
min/+Vdr
+/+, Apc
min/+Vdr
+/- and Apc
min/+Vdr
-/- mice. Each dot corresponds to one lesion
analyzed and the horizontal line indicates the mean. (d) Quantification of b-catenin nuclear level in colonic adenomas and carcinomas from Apc
min/
+Vdr
+/+, Apc
min/+Vdr
+/- and Apc
min/+Vdr
-/- mice. Each dot corresponds to one lesion analyzed and the horizontal line indicates the mean. (a, c, d) The p-
values for one-way ANOVA analysis are shown. Asterisks indicate significant differences between groups upon Bonferroni multiple comparison post-
test.
doi:10.1371/journal.pone.0023524.g002
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reflected in an increased expression of several b-catenin/TCF
target genes: qRT-PCR analysis revealed higher levels of AXIN2,
LEF1 and c-MYC mRNA in shVDR than in shControl cells
(Figure 4e). Additionally, the inhibition of the expression of b-
catenin/TCF target genes by 1,25(OH)2D3 was reduced in
shVDR cells (Figure 4e). The reduction of VDR expression by
shRNA was also analyzed by qRT-PCR (Figure 4e) and translated
into undetectable protein levels ([31] and data not shown). As
control we studied the expression of CDH1/E-cadherin and
CYP24A1 in these cells, two 1,25(OH)2D3 target genes. The
induction of both genes was drastically inhibited in shVDR cells
(Figure S2a).
Next, we extended our studies to other human colon cancer cell
lines. VDR knock-down in HCT116 and HT29 cells also promoted
an increase in nuclear b-catenin levels (Figure S2b) and the
activation of TCF/LEF-dependent transcription (Figure S2c),
leading to a higher expression of the b-catenin target genes AXIN2
and DKK1 (Figure S2d). Such gene regulation was accompanied by
a general loss of epithelial organization (Figure S2b). As expected,
the reduction of VDR expression blocked the capacity of
1,25(OH)2D3 to induce its target gene CYP24A1 (Figure S2d).
However, and contrarily to data from SW480-ADH cells,
1,25(OH)2D3 had no effect on b-catenin location or transcriptional
activity in HCT116 and HT29 cells (Figure S2d and data not
shown). The reason may be that these cells express high level of E-
cadherin and thus b-catenin is located at the plasma membrane in
the absence of 1,25(OH)2D3.
Transient expression of exogenous wild type VDR in VDR-
negative human SW620 metastatic colon cancer cells reduced
their high nuclear b-catenin levels (Figure S3). By contrast, VDR-
DAF2 and VDR-L417S mutants that are unable to bind b-catenin
and recruit classical coactivators [21] did not change the nuclear
content of b-catenin (Figure S3). Likewise, the expression of a
VDR mutant unable to bind classical coactivators but capable to
bind b-catenin (VDR-E420Q) [21] had no effect on b-catenin
nuclear content in SW620 cells (Figure S3).
The observed increase in nuclear b-catenin content by VDR
knock-down is not a consequence of the reduced activity of the
kinases CK-Ia or GSK-3b since the level of b-catenin phosphor-
ylation at Ser45 or Ser33/Ser37/Thr41 was unaltered in shVDR
SW480-ADH cells (Figure S4a). As b-catenin phosphorylation at
Ser552 and Ser675 by protein kinase A and/or AKT has been
proposed to promote b-catenin nuclear location and/or transcrip-
tional activity [32-34], we also analyzed the possibility that these
kinases were involved in the effect of VDR knock-down on b-
catenin. We found that b-catenin phosphorylation at Ser552 and
Ser675 was reduced in shVDR SW480-ADH cells (Figure S4).
Next, we aimed to confirm the effect of VDR deficiency on b-
catenin target genes in vivo. To this end, we analyzed by
immunofluorescence and quantified the level of expression of
two b-catenin/TCF target genes (Ccnd1/Cyclin D1 and Lef1)i n
colon ACF and carcinomas of Apc
min/+Vdr
+/+, Apc
min/+Vdr
+/- and
Apc
min/+Vdr
-/- mice. Accordingly with the data from cultured cells,
a significant increased expression of both gene products was found
in the lesions of Apc
min/+Vdr
-/- mice (Figure 5).
Finally, we analyzed the degree of differentiation of ACF and
carcinomas present in the colon of Apc
min/+Vdr
+/+, Apc
min/+Vdr
+/2
and Apc
min/+Vdr
-/- mice. Antibodies against cytokeratins (pan-
cytokeratin) and villin1 as markers of epithelial differentiation were
used (Figure S5). ACF expressed very low levels of these proteins as
expected from the progenitor phenotype imposed by high Wnt/b-
catenin signaling (Figure 6a, 6b). In carcinomas the expression of
both markers was heterogeneous (Figure 6c, 6d), which agrees with
the heterogeneous expression of b-catenin previously described
(Figure S1a). No substantial differences in the expression of
cytokeratins and villin1 were found between lesions of Apc
min/+
Vdr
+/+, Apc
min/+Vdr
+/2 and Apc
min/+Vdr
-/- mice, suggesting that
these two differentiation markers are lost early during colon
tumorigenesis, probably as a consequence of the initial activation
of the Wnt/b-catenin pathway.
Discussion
The level of nuclear b-catenin defines the strength of the Wnt/
b-catenin signaling and in consequence the fate and phenotype of
many types of normal and cancer cells. Aberrant activation of
Wnt/b-catenin signaling due to alterations in components of the
pathway is responsible for the initiation of most human colon
cancers, which highlights the importance of controlling nuclear b-
catenin accumulation [28,29,35]. Although the initiation of colon
tumorigenesis is considered clonal [36], colon carcinomas show
largely heterogeneous nuclear b-catenin expression. This is known
as the b-catenin paradox and has led to search for alternative
pathways modulating b-catenin location and activity. Among
them, K-RAS mutation and myofibroblasts-derived HGF have
been recently proposed to increase b-catenin nuclear content
[28,29].
Very little is known about mechanisms to diminish the level of
b-catenin within the nucleus. We have described that
1,25(OH)2D3 and several less calcemic analogs interfere the
Wnt/b-catenin pathway in a series of human colon cancer cell
lines in several modes: they increase the binding of VDR to b-
catenin hampering the formation of b-catenin/TCF complexes,
induce the expression of the Wnt inhibitor DKK1, and promote
the relocation of b-catenin from the nucleus towards the plasma
membrane where it binds E-cadherin at adherens junctions [13,14].
Putative mechanisms for this latter effect include the induction of
b-catenin nuclear export or the sequester of newly synthesized
and/or cytosolic b-catenin protein by E-cadherin, whose expres-
sion is strongly induced by 1,25(OH)2D3. Another mechanism of
Wnt/b-catenin inhibition in colon cancer has been proposed by
Kaler and cols.: 1,25(OH)2D3 decreases the synthesis and secretion
Figure 4. VDR knock-down in SW480-ADH cells enhances b-catenin/TCF transcriptional activity and reduces the inhibitory effect of
1,25(OH)2D3 on Wnt/b-catenin pathway. (a) Diagram of the 7xTCF/LEF-eGFP-SV40-mCherry lentiviral construct used to infect shControl and
shVDR SW480-ADH cells. (b) Representative phase-contrast and fluorescence images showing the expression of eGFP and mCherry in SW480-ADH
cells infected with the 7xTCF/LEF-eGFP-SV40-mCherry vector. Arrowheads indicate similarly infected cells that have variable expression of eGFP. Scale
bars, 20 mm. (c) Flow cytometry analysis of eGFP expression in shControl and shVDR SW480-ADH cells infected (mCherry positive) with the 7xTCF/LEF-
eGFP-SV40-mCherry vector and treated with 1,25(OH)2D3 or vehicle for 96 h. Percentage of cells in each gate is indicated. (d) Quantification of the
flow cytometry data showing the average expression of eGFP in the infected mCherry-positive cells. Data correspond to three independent
experiments. The p-value for one-way ANOVA analysis is shown. Asterisks indicate significant differences between groups upon Bonferroni multiple
comparison post-test. (e) Analysis by qRT-PCR of VDR, AXIN2, LEF1 and c-MYC mRNA expression in shControl and shVDR SW480-ADH cells treated with
1,25(OH)2D3 or vehicle for 48 h. The geometric average of the expression of SDHA and TBP housekeeping genes was used for RNA expression
normalization as indicated in Materials and Methods. Numbers indicate the percentage of inhibition by 1,25(OH)2D3 treatment in each cell type. Data
correspond to three independent experiments.
doi:10.1371/journal.pone.0023524.g004
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the Wnt/b-catenin pathway in colon cancer cells through the
blockade of b-catenin phosphorylation by GSK-3b [37]. However,
the function of all these cell-autonomous and non-cell-autonomous
mechanisms in vivo remained unknown.
In this study we examined whether VDR deficiency alters b-
catenin nuclear content and Wnt/b-catenin pathway in the most
commonly used animal model for colon cancer, the Apc
min/+ mice.
Our results show that Vdr deficiency in Apc
min/+ mice increases
nuclear b-catenin levels and expression of Wnt/b-catenin target
genes and, in line with these effects, enhances total colon tumor
load. Consistently, knocking-down VDR by shRNA in human
colon cancer cells enhances the nuclear content of b-catenin, its
transcriptional activity, and the expression of Wnt/b-catenin
target genes. Furthermore, transient restoration of wild type VDR
expression in VDR-negative human SW620 colon cancer cells
decreases nuclear b-catenin level, whereas VDR-DAF2, VDR-
L417S or VDR-E420Q mutants, unable to bind classical
coactivators and activate gene transcription [21], did not.
Curiously, among them only VDR-E420Q is capable to bind b-
catenin [21] and its re-expression in Vdr
-/- mice rescues alopecia
but not rickets phenotype [38]. It seems, therefore, that nuclear b-
catenin level and activity depend on the capacity of VDR to
recruit classical transcriptional coactivators.
Our data show that VDR knock-down in SW480-ADH cells
does not affect b-catenin phosphorylation by CK-Ia or GSK-3b,
discarding a role of VDR regulating total b-catenin accumulation.
Whereas nuclear b-catenin level increases in the absence of VDR,
the total cellular amount of b-catenin protein is not altered (Figure
S4a). Unexpectedly, we also found that the phosphorylation of b-
catenin at Ser552 and Ser675 proposed to increase b-catenin
transcriptional activity is reduced in shVDR SW480-ADH cells.
However, the putative inhibitory effect that the reduction of these
phosphorylations may have on b-catenin transcriptional activity
seems to be overpassed by the effect of VDR deficiency increasing
b-catenin nuclear translocation. Altogether, these data suggest that
VDR does not control b-catenin degradation but most probably
favours its redistribution to the cell nucleus.
Our results reveal a novel in vivo function of VDR as crucial
modulator of Wnt/b-catenin signal strength in colon cancer. The
finding that VDR deficiency does not change the number of tumors
but increases tumor load indicates that VDR does not block the
initial mutations that provoke the early activation of the Wnt/b-
catenin pathway, but that it preferentially has a long term
protective effect on tumor growth by limiting the strength of the
Wnt/b-catenin oncogenic signal. Concordant with our results, a
very recent report has shown that Apc
min/+Vdr
-/- mice present
larger intestinal tumors than Apc
min/+Vdr
+/+ mice, although the
molecular mechanisms behind this phenotype was not investigated
[39]. The concordance of the two parallel studies confirms their
main findings.
The results of our study are relevant for the clinic, as VDR
expression is downregulated in approximately two-thirds of
advanced colon tumors associated to the upregulation of SNAI1
and SNAI2 genes that code for SNAIL1/SNAIL2 transcriptional
repressors [15,16,40]. VDR loss may contribute to overactivate
the Wnt/b-catenin pathway and so, to accelerate tumor growth
and malignization. A few studies have proposed VDR expression
as a marker of good prognostic in colon cancer and showed its
correlation with high tumor differentiation and absence of node
involvement. However, the low number of patients analyzed does
not allow definitive conclusions [41–43]. Patients with carcinomas
at early stages that still express VDR could benefit from therapy
with 1,25(OH)2D3 compounds that would potentially reduce
Wnt/b-catenin oncogenic function. However, when VDR expres-
sion is lost at advanced stages, tumors will not only be refractory to
this type of treatment but will also acquire higher levels of nuclear
b-catenin and enhanced Wnt/b-catenin signaling.
Materials and Methods
Ethics statement
Animal work within this article was carried out in strict
accordance with the recommendations by the European Union
(ECC directive 86/609/EEC, November 1986) and all the
experiments were approved by the Ethical Committee for Animal
Experimentation of the Consejo Superior de Investigaciones
Cientı ´ficas (Approval ID: PN2010-IE81). All efforts were made
to minimize animal suffering. The work involving human samples
was conducted according to the principles expressed in the
Declaration of Helsinki. The study was approved by the Research
Ethics Board of Vall d’Hebro ´n Institute of Oncology (Approval
ID: PR(IR)79/2009). All patients provided written informed
consent for the collection of samples and subsequent analysis.
Cell culture and gene transfer
Human SW480-ADH, HT29, HCT116 and SW620 colon
cancer cells were grown in DMEM supplemented with 10% FCS
and 2 mM L-glutamine (all from Invitrogen, Carlsbad, CA).
SW480-ADH cells are a subpopulation derived from SW480 cell
line that express substantial VDR levels and are thus responsive to
1,25(OH)2D3 [13]. All experiments using 1,25(OH)2D3 were
performed in DMEM supplemented with charcoal-treated FCS to
remove liposoluble hormones. Cells were treated with 100 nM
1,25(OH)2D3 or the corresponding vehicle/isopropanol concen-
tration for the indicated times.
To knock-down VDR expression, cells were infected with
lentiviral particles containing a shRNA targeting VDR (Sigma-
Aldrich, St Louis, MO) and selected by puromycin treatment as
previously described [31]. shControl cells were infected with
lentiviruses bearing a non-targeting shRNA that activates the
RISC complex and the RNA interference pathway but that
contains at least five mismatched nucleotides compared with any
human gene (Sigma-Aldrich). To reconstitute VDR expression,
SW620 cells were transiently transfected with the expression
vector for human VDR wild type or several mutants (VDR-DAF2,
VDR-L417S and VDR-E420Q, kindly provided by Dr. A.
Aranda, Instituto de Investigaciones Biome ´dicas, Madrid, Spain)
or with the empty vector (pSG5) using jetPEI transfection reagent
(PolyPlus Transfection, Illkirch, France), and cells were analyzed
after 48 h.
Figure 5. Colonic ACF and carcinomas in Apc
min/+Vdr
-/- mice have elevated expression of b-catenin/TCF target genes Ccnd1/Cyclin D1
and Lef1. Quantification of Cyclin D1 (a) and Lef1 (d) protein expression in colonic lesions from Apc
min/+Vdr
+/+, Apc
min/+Vdr
+/- and Apc
min/+Vdr
-/- mice.
Each dot corresponds to one lesion analyzed and the horizontal line indicates the mean. The p-values for one-way ANOVA analysis are shown.
Asterisks indicate significant differences between groups upon Bonferroni multiple comparison post-test. Representative immunofluorescence
images showing b-catenin and Cyclin D1 (b, c) or b-catenin and Lef1 (e, f) expression and localization in colon ACF (b, e) and carcinomas (c, f) from
Apc
min/+Vdr
+/+ and Apc
min/+Vdr
-/- mice. Scale bars, 50 mm (b, e) and 200 mm (c, f). Asterisks indicate an unspecific staining.
doi:10.1371/journal.pone.0023524.g005
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trol and shVDR SW480-ADH cells were infected with lentiviruses
containing the 7xTCF/LEF-eGFP-SV40-mCherry vector [30]
and analyzed by flow cytometry. In the case of shControl and
shVDR HCT116 and HT29 cells, they were transiently
cotransfected using jetPEI with the pRLTK plasmid (Promega,
Madison, WI) containing the Renilla reniformis luciferase gene
(RLuc) under the control of the thymidine kinase promoter and with
the TOP-Flash or FOP-Flash plasmid containing four multi-
merised copies of wild type (TOP-Flash) or mutated (FOP-Flash)
TCF/LEF-binding sites upstream of a minimal c-fos promoter
driven the expression of the Firefly luciferase gene (Luc) (kindly
provided by Dr. H. Clevers, Hubrecht Laboratory, Utrecht, The
Netherlands). Luc and RLuc activities were separately measured
48 h after transfection using the Dual Luciferase Kit (Promega).
Luc activity was normalized to RLuc and the TOP-Flash/FOP-
Flash ratio calculated.
Mouse colony and tissue isolation
The Vdr
+/2 and Apc
min/+ mice (kindly provided by Drs. M. B.
Demay, Harvard Medical School, Boston, MA and E. Batlle,
Institute for Research in Biomedicine, Barcelona, Spain, respec-
tively) were previously described [4,44]. Apc
min/+Vdr
+/+, Apc
min/+
Vdr
+/2 and Apc
min/+Vdr
-/- mice were obtained by appropriate
crossings. All mice were kept in a virus- and parasite-free barrier
facility. They were exposed to a 12 h light and dark cycle and
allowed free access to autoclaved water and chow. At five months
of age mice were sacrificed. The mice were dissected and the small
intestine and colon removed and flushed with PBS. Intestines were
then wound into ‘‘Swiss’’ rolls which were subsequently fixed O/N
in 10% neutral-buffered formalin solution (Sigma-Aldrich). Then,
tissues were embedded in paraffin, sectioned, deparaffinized,
hydrated and stained with hematoxylin/eosin for microscopic
tumor scoring. The number of tumors was counted and the size
(diameter) of each tumor was measured blindly by two
independent researchers using a conventional light microscope.
Immunofluorescence and confocal microscopy
Cells growing on coverslips were rinsed once in PBS, fixed in
cold methanol for 1 min and rinsed in PBS. Non-specific sites were
blocked by incubation with PBS containing 5% BSA for 1 h at
RT. Then, cells were incubated with the primary antibodies (E-
cadherin, BD Biosciences, San Jose, CA; b-catenin, BD Biosci-
ences and Abcam, Cambridge, UK; b-tubulin, Sigma-Aldrich;
VDR, Millipore, Billerica, MA) diluted 1/100 in PBS O/N at
4uC. After four washes in PBS, cells were incubated with
secondary fluorophore-conjugated antibodies (Invitrogen) and
Hoechst 33342 (Sigma-Aldrich) for 1 h at RT, washed and
mounted in Vectashield (Vector Laboratories, Burlingame, CA).
Cell imaging was performed on a Leica TCS SP5 DMI6000
microscope (Leica, Wetzlar, Germany) using argon ion (488 nm),
HeNe (543 nm) and violet diode (405 nm) lasers. Images were
acquired sequentially by direct register using LAS AF Leica
Confocal Software.
For tissue immunofluorescence, formalin-fixed paraffin-embed-
ded sections of mouse small intestine and colon or human colon
tumors were prepared and immunolabelled as described elsewhere
[27]. Briefly, tissues were sectioned at 4 mm, deparaffined and
rehydrated using xylene and a series of graded ethanol. Antigens
were retrieved by microwaving the sections immersed in 10 mM
citrate buffer (pH 6.0) for 10 min. Then, sections were cooled at
RT for 20 min, rinsed in PBS and permeabilized with 0.2%
Triton X-100. Non-specific binding was blocked by incubating the
sections in PBS 5% BSA for 1 h at RT. Immunofluorescence
staining was carried out incubating the sections with the primary
antibodies (b-catenin, BD Biosciences and Abcam; Cyclin D1,
Abcam; Lef1, Cell Signaling Technology, Danvers, MA; pan-
cytokeratin, Santa Cruz Biotechnology, Santa Cruz, CA; villin1,
LifeSpan Biosciences, Seattle, WA) diluted 1/100 in PBS O/N at
4uC. After four washes in PBS, cells were incubated with
secondary fluorophore-conjugated antibodies and Hoechst 33342
for 1 h at RT, washed and mounted in Vectashield. Cell imaging
was performed as described above for cell immunofluorescence.
For the quantification of the fluorescent signal of tissue
immunofluorescences we used the MacBiophotonics ImageJ
software. In brief, we defined Regions of Interest (ROI) and
obtained the integrated density of the ROI for the green and the
red channels corresponding to specific antibody staining. In
parallel, we measured the Hoechst integrated density of each ROI
and divided it by a standard nucleus signal. The standard nucleus
signal was calculated as the average integrated density of ten nuclei
taken at random. The resulting values corresponded to the
number of nuclei and, therefore, to the number of cells present in
each ROI. We finally divided the integrated density of the proteins
of interest in the ROI by the number of cells present in the same
ROI. This value indicates the level of expression of the proteins of
interest per cell. To measure nuclear b-catenin levels we previously
used MacBiophotonics ImageJ software to generate an image
where the positive staining corresponded to coincident Hoechst
(blue channel) and b-catenin (red channel) signals. To quantify the
level of nuclear b-catenin in SW620 cells ectopically expressing
different VDR variants, we adapted the above mentioned method
to single cell measurements. Nuclear b-catenin level (red vs blue
channel) was calculated in cells transfected with empty vector or
with wild type or mutant VDR (green channel). One hundred cells
expressing exogenous VDRs (green positive) or the empty vector
(green negative) were estimated in each condition and values were
represented as arbitrary units. All quantifications were performed
blindly by two independent researchers.
Flow cytometry
One million of shControl and shVDR SW480-ADH cells
infected with 7xTCF/LEF-eGFP-SV40-mCherry vector were
trypsinized and resuspended in DMEM 10% FCS. Then, cells
were washed with PBS and resuspended in 1 ml PBS. DNA was
stained with DAPI (2 mg/ml; Sigma-Aldrich) in order to exclude
dead, apoptotic or clumped cells. Acquisition was performed using
Beckman-Coulter Moflo Cytometer (Fullerton, CA) and the data
obtained was analyzed with FCS Express Version 3 Software.
RNA extraction and quantitative RT-PCR
RNA was extracted from cultured cells using RNeasy Mini Kit
(Qiagen, Hilden, Germany) and retrotranscribed using the High-
Capacity cDNA Archive Kit (Applied Biosystems, Framingham,
Figure 6. Vdr depletion does not affect the differentiation status of colon ACF and carcinomas in Apc
min/+ mice. Representative
immunofluorescence images showing b-catenin and villin1 (a, c) or b-catenin and pan-cytokeratin (b, d) expression and localization in colon ACF (a, b)
and carcinomas (c, d) from Apc
min/+Vdr
+/+ and Apc
min/+Vdr
-/- mice. Dotted-lines delimit ACF. Numbers indicate regions with different pattern of
expression of the analyzed proteins within the same tumor: 1) high b-catenin, low villin1/cytokeratins; 2) low b-catenin, high villin1/cytokeratins. Scale
bars, 50 mm (a, b) and 200 mm (c, d).
doi:10.1371/journal.pone.0023524.g006
VDR Controls Wnt/b-Catenin Signaling In Vivo
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23524MA). Target gene RNA expression was measured by quantitative
RT-PCR in relation to the geometric average of two reference
housekeeping genes, succinate dehydrogenase complex subunit A
(SDHA) and TATA box binding protein (TBP), following the
recommendations by Vandesompele et al. [45]. Oligonucleotides
for VDR, CDH1 and SDHA were previously reported [15], AXIN2
(sense 59-AGTCAGCAGAGGGACAGGAA-39, antisense 59-
GTGGACACCTGCCAGTTTCT-39), LEF1 (sense 59-CGAA-
GAGGAAGGCGATTTAG-39, antisense 59-GTCTGGCCACC-
TCGTGTC-39), c-MYC (sense 59-TGGATTTTTTTCGGGTA-
GTGG-39, antisense 59-GTCGTAGTCGAGGTCATAGTTCC-
39) and TBP (sense 59-CGGCTGTTTAACTTCGCTTC-39,
antisense 59-CACACGCCAAGAAACAGTGA-39). Primers were
designed to recognize regions of the mRNAs codified by different
exons to avoid genomic DNA amplification. In addition, control
samples in which reverse transcription was performed without
reverse transcriptase were always included in the quantitative PCR
runs. The level of CYP24A1 and DKK1 RNA were measured in
relation to that of 18S rRNA using the comparative CT method
and TaqMan probes (Applied Biosystems). The quantitative PCR
reaction was performed in an ABI Prism 7900 HT thermal cycler
using SYBR or TaqMan Gene Expression Master Mixes (all from
Applied Biosystems). Thermal cycling consisted of a denaturing
step at 95uC for 10 min and 40 cycles of denaturing at 95uC for
15 s and annealing and elongation at 60uC for 60 s.
Western blotting
Whole-cell extracts were prepared by washing the monolayers
twice in PBS and cell lysis by incubation in RIPA buffer (50 mM
Hepes pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 10% glycerol,
4 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% deoxycholate)
plus phosphatase- and protease-inhibitor mixture (25 mM b-
glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 1 mM PMSF,
10 mg/ml leupeptin, 10 mg/ml aprotinin) for 15 min on ice
followed by centrifugation at 13,000 rpm for 10 min at 4uC.
Western blotting of cell lysates was performed by electrophoresis in
SDS-PAGE and protein transfer to Immobilon P membranes
(Millipore). The membranes were incubated with the appropriate
primary and secondary horseradish peroxidase-conjugated anti-
bodies, and the antibody binding was visualized using the ECL
detection system (GE Healthcare, Chalfont St Giles, UK). The
following primary antibodies were used: mouse monoclonal
against E-cadherin, b-catenin (BD Biosciences) and active-b-
catenin (anti-ABC) (Millipore); rat monoclonal against VDR
(Millipore); and rabbit polyclonal against phospho-b-catenin-
Ser552, phospho-b-catenin-Ser45, phospho-b-catenin-Ser675,
and phospho-b-catenin-Ser33/Ser37/Thr41 (Cell Signaling).
Quantification was done by densitometry using ImageJ software.
Statistical analysis
Statistical significance was assessed by unpaired t test with
Welch’s correction when two groups of values were compared. For
multiple group comparisons we used an unpaired one-way
ANOVA analysis with Bonferroni multiple comparison post-test.
All calculations were performed using the GraphPad Prism 5
software (San Diego, CA). Differences were considered significant
when p,0.05.
Supporting Information
Figure S1 b-Catenin expression and localization is
heterogeneous in colon carcinomas from Apc
min/+ mice
and in human colon tumors. (a) Representative immunoflu-
orescence image showing b-catenin expression and localization in
colon carcinomas from Apc
min/+ mice. Numbers indicate regions
with different pattern of b-catenin expression and localization: 1)
high cytosolic and nuclear; 2) low membrane and cytosolic. Scale
bar, 500 mm. (b) Representative immunofluorescence images
showing b-catenin expression and localization in human colon
tumors. Numbers indicate regions with different pattern of b-
catenin expression and localization within the same tumor: upper
panel: 1) membrane and cytosolic; 2) very high cytosolic and
nuclear; 3) high membrane and cytosolic; lower panel: 1,
membrane; 2, high cytosolic and nuclear. Scale bar, 100 mm.
(TIF)
Figure S2 VDR knock-down in human HCT116 and
HT29 colon cancer cells increases b-catenin nuclear
levels and transcriptional activity. (a) Analysis by qRT-PCR
ofCYP24A1and CDH1/E-cadherinmRNAexpressioninshControl
and shVDR SW480-ADH cells treated with 1,25(OH)2D3 or
vehicle for 48 h. Data correspond to three independent experi-
ments. (b) Representative immunofluorescence images showing b-
catenin expression and localization in HCT116 and HT29 cells
infected with lentiviruses expressing shVDR or shControl. Scale
bar, 100 mm. (c) Cells were transfected with the wild type (TOP-
Flash) or mutated (FOP-Flash) b-catenin/TCF reporter plasmid
and luciferase activity was measured 48 h later. Values were
represented as the TOP-Flash/FOP-flash ratio and related to
shControl cells. Data correspond to five independent experiments.
The p-values for unpaired t test with Welch’s correction are
indicated. (d) Analysis by qRT-PCR of VDR, CYP24A1, AXIN2 and
DKK1 mRNA expression in shControl and shVDR HCT116 and
HT29 cells treated with 1,25(OH)2D3 or vehicle for 48 h. Data
correspond to three independent experiments. (a, d) The geometric
average of the expression of SDHA and TBP housekeeping genes
(for CDH1, VDR and AXIN2) or the expression of 18S rRNA (for
CYP24A1 and DKK1) was used for RNA expression normalization
as indicated in Materials and Methods.
(TIF)
Figure S3 Exogenous wild type VDR expression reduces
nuclear b-catenin levels in SW620 cells. (a) Representative
immunofluorescence images showing b-catenin and VDR expres-
sion and localization in SW620 cells transiently transfected with
wild type (WT) VDR, or the VDR-DAF2, VDR-L417S or VDR-
E420Q mutants for 48 h. Scale bar, 50 mm. (b) Quantification of
nuclear b-catenin level in SW620 cells transiently transfected with
empty vector (pSG5), wild type VDR or the indicated VDR
mutants for 48 h. One hundred cells per condition were studied.
Each dot corresponds to one cell analyzed and the horizontal line
indicates the mean. The p-value for one-way ANOVA analysis is
shown. Asterisks indicate significant differences between groups
upon Bonferroni multiple comparison post-test.
(TIF)
Figure S4 Effect of VDR absence on b-catenin phos-
phorylation by several kinases. (a) Western blot analysis of b-
catenin phosphorylation in residues targeted by GSK-3b (Ser33,
Ser37 and Thr41), CK-Ia (Ser45), PKA (Ser552 and Ser675) or
AKT (Ser552) in SW480-ADH shControl and shVDR cells
treated with 1,25(OH)2D3 or vehicle for 72 h. Antibodies that
specifically recognize each type of phosphorylated b-catenin or the
unphosphorylated protein in Ser37 or Thr41 (active-b-catenin)
were used. VDR and E-cadherin expression in the same extracts
was shown as a control. A representative experiment of three
performed is shown. (b) Quantification of the data obtained in
three independent experiments performed as in (a). Phosphory-
lated b-catenin levels were normalized to total b-catenin.
(TIF)
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tion markers in mouse colon tissue. Representative
immunofluorescence images showing b-catenin and pan-cytoker-
atin (a) or b-catenin and villin1 (b) staining of mouse normal colon
tissue. Both pan-cytokeratin and villin1 markers stain the
differentiated cells located at the upper part of the normal mouse
colon crypts. Scale bar, 50 mm.
(TIF)
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